E-Cigarette Use Among US Adults in the 2021 Behavioral Risk Factor Surveillance System Survey.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
medline:
6
11
2023
pubmed:
3
11
2023
entrez:
3
11
2023
Statut:
epublish
Résumé
After the initial disruption from the COVID-19 pandemic, it is unclear how patterns of e-cigarette use in the US have changed. To examine recent patterns in current and daily e-cigarette use among US adults in 2021. This cross-sectional study used data from the 2021 Behavioral Risk Factor Surveillance System (BRFSS) database. The BRFSS is the largest national telephone-based survey of randomly sampled adults in the US. Adults aged 18 years or older, residing in 49 US states (all except Florida), the District of Columbia, and 3 US territories (Guam, Puerto Rico, and the US Virgin Islands), were included in the data set. Data analysis was performed in January 2023. The main outcome was age-adjusted prevalence of current and daily e-cigarette use overall and by participant characteristics, state, and territory. Descriptive statistical analysis was conducted, applying weights to account for population representation. This study included 414 755 BRFSS participants with information on e-cigarette use. More than half of participants were women (51.3%). In terms of race and ethnicity, 0.9% of participants were American Indian or Alaska Native, 5.8% were Asian, 11.5% were Black, 17.3% were Hispanic, 0.2% were Native Hawaiian or Other Pacific Islander, 62.2% were White, 1.4% were of multiple races or ethnicities, and 0.6% were of other race or ethnicity. Individuals aged 18 to 24 years comprised 12.4% of the study population. The age-standardized prevalence of current e-cigarette use was 6.9% (95% CI, 6.7%-7.1%), with almost half of participants using e-cigarettes daily (3.2% [95% CI, 3.1%-3.4%]). Among individuals aged 18 to 24 years, there was a consistently higher prevalence of e-cigarette use, with more than 18.6% reporting current use and more than 9.0% reporting daily use. Overall, among individuals reporting current e-cigarette use, 42.2% (95% CI, 40.7%-43.7%) indicated former combustible cigarette use, 37.1% (95% CI, 35.6%-38.6%) indicated current combustible cigarette use, and 20.7% (95% CI, 19.7%-21.8%) indicated never using combustible cigarettes. Although relatively older adults (aged ≥25 years) who reported current e-cigarette use were more likely to report former or current combustible cigarette use, younger adults (aged 18-24 years) were more likely to report never using combustible cigarettes. Notably, the proportion of individuals who reported current e-cigarette use and never using combustible cigarettes was higher in the group aged 18 to 20 years (71.5% [95% CI, 66.8%-75.7%]) compared with those aged 21 to 24 years (53.0% [95% CI, 49.8%-56.1%]). These findings suggest that e-cigarette use remained common during the COVID-19 pandemic, particularly among young adults aged 18 to 24 years (18.3% prevalence). Notably, 71.5% of individuals aged 18 to 20 years who reported current e-cigarette use had never used combustible cigarettes. These results underscore the rationale for the implementation and enforcement of public health policies tailored to young adults.
Identifiants
pubmed: 37921768
pii: 2811322
doi: 10.1001/jamanetworkopen.2023.40859
pmc: PMC10625038
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2340859Références
JAMA Netw Open. 2021 Dec 1;4(12):e2140880
pubmed: 34962556
JAMA Netw Open. 2022 Nov 1;5(11):e2240671
pubmed: 36342713
Tob Use Insights. 2023 Mar 7;16:1179173X231161313
pubmed: 36911177
MMWR Morb Mortal Wkly Rep. 2019 Nov 15;68(45):1013-1019
pubmed: 31725711
Nicotine Tob Res. 2019 Jan 1;21(1):71-80
pubmed: 29490078
Nicotine Tob Res. 2021 Feb 16;23(3):527-534
pubmed: 32421191
JAMA Netw Open. 2020 Nov 2;3(11):e2020816
pubmed: 33180127
BMC Public Health. 2023 Jun 6;23(1):1080
pubmed: 37280552
Children (Basel). 2022 Oct 31;9(11):
pubmed: 36360406
Respir Med. 2022 Aug-Sep;200:106925
pubmed: 35797927
JAMA Netw Open. 2022 Jul 1;5(7):e2223266
pubmed: 35867060
Epidemiology. 2022 Jul 1;33(4):523-532
pubmed: 35394965
MMWR Morb Mortal Wkly Rep. 2023 May 05;72(18):475-483
pubmed: 37141154
BMC Psychol. 2022 Aug 15;10(1):201
pubmed: 35971158
MMWR Morb Mortal Wkly Rep. 2023 Mar 10;72(10):270
pubmed: 36893067
Lancet Reg Health Am. 2023 Jun 07;23:100528
pubmed: 37497394
JAMA Netw Open. 2020 Jan 3;3(1):e1920255
pubmed: 32003818
Drug Alcohol Depend. 2019 Aug 1;201:85-93
pubmed: 31200279
Behav Sci (Basel). 2022 Nov 16;12(11):
pubmed: 36421749
BMC Public Health. 2020 Oct 09;20(1):1518
pubmed: 33032554
Prev Chronic Dis. 2022 Jun 02;19:E29
pubmed: 35653765
Int J Environ Res Public Health. 2020 Sep 16;17(18):
pubmed: 32948084
JAMA Intern Med. 2020 Oct 1;180(10):1394-1398
pubmed: 32897288
JAMA Netw Open. 2020 Dec 1;3(12):e2027572
pubmed: 33270127
Drug Alcohol Depend. 2018 Jul 1;188:60-63
pubmed: 29753155
Public Health Rep. 2023 May-Jun;138(3):483-492
pubmed: 35684996
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):397-405
pubmed: 35298455
MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1736-1742
pubmed: 33211681
Nicotine Tob Res. 2023 Jan 5;25(2):350-355
pubmed: 35639822
JAMA. 2019 Nov 12;322(18):1824-1827
pubmed: 31524940